ArticleHaematologica2016
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparative Analysis of Primary and Second Primary Multiple Myeloma: A Propensity Score-Matched Study.Clinical Medicine Insights. Oncology · 2025Article
- Article
- Article
- Real-World Pitfalls of Analyzing Real-World Data: A Cautionary Note and Path Forward.JCO clinical cancer informatics · 2023Article
- Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.Blood advances · 2023Article
- Autologous transplant and second malignancies in MM.Blood advances · 2023Article
- The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma.Current oncology (Toronto, Ont.) · 2023Article
- Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study.Frontiers in oncology · 2023Article
- Article
- Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.BMJ case reports · 2022Article
- Second primary malignancies in multiple myeloma: A review.Blood reviews · 2021Review
- Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient.Case reports in hematology · 2021Article
- Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.Scientific reports · 2020Article
- Treatment and disease-related complications in multiple myeloma: Implications for survivorship.American journal of hematology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.